This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately.
What Makes Aclaris (ACRS) a New Buy Stock
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Aclaris Therapeutics (ACRS) Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics, Inc. (ACRS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 15.20% and 3.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Aclaris' Alopecia Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
by Zacks Equity Research
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
Humana (HUM) Includes Methodist Healthcare in its Network
by Zacks Equity Research
Humana Inc. (HUM) recently entered into an agreement with Methodist Healthcare to provide better service to its patients.
Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
by Zacks Equity Research
Aclaris Therapeutics, Inc. (ACRS) shares rose over 8% in the last trading session.
Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
by Zacks Equity Research
Aclaris Therapeutics (ACRS) in the Medical-Drugs space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.